AtriCure, Inc. (ATRC)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$51.52-1.79%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · ATRC
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On July 23, 2026 , AtriCure, Inc. issued a press release regarding its financial results for the second quarter ended June 30, 2026. The Company will hold a conference call on July 23, 2026 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
The filing details an amendment to the stock incentive plan, increasing the number of shares available.
Results of Operations and Financial Condition. On May 6, 2026, AtriCure, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2026. The Company held a conference call on May 5, 2026 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release, as corrected, is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On May 5, 2026 , AtriCure, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2026. The Company will hold a conference call on May 5, 2026 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On February 17, 2026 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2025. The Company will hold a conference call on February 17, 2026 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On January 12, 2026, AtriCure issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Entry into a Material Definitive Agreement. On January 9, 2026 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into a First Amendment (“ First Amendment ”) to Credit Agreement (as amended, the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A., as bookrunner and lea…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Results of Operations and Financial Condition. On October 29, 2025 , AtriCure, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2025. The Company will hold a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On October 29, 2025 , AtriCure, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2025. The Company will hold a conference call on October 29, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On July 29, 2025 , AtriCure, Inc. issued a press release regarding its financial results for the second quarter ended June 30, 2025. The Company will hold a conference call on July 29, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
The filing is about an amendment to the stock incentive plan, not a management change.
Results of Operations and Financial Condition. On April 29, 2025 , AtriCure, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2025. The Company will hold a conference call on April 29, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On February 12, 2025 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2024. The Company will hold a conference call on February 12, 2025 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On January 13, 2025, AtriCure issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On October 29, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the third quarter ended September 30, 2024. The Company will hold a conference call on October 29, 2024 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On July 30, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the second quarter ended June 30, 2024. The Company will hold a conference call on July 30, 2024 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
The filing pertains to an amendment of the stock incentive plan, not a management change.
Results of Operations and Financial Condition. On May 1, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the first quarter ended March 31, 2024. The Company will hold a conference call on May 1, 2024 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Results of Operations and Financial Condition. On February 15, 2024 , AtriCure, Inc. issued a press release regarding its financial results for the fourth quarter and full-year ended December 31, 2023. The Company will hold a conference call on February 15, 2024 at 4:30 p.m. Eastern Time to discuss the financial results. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference. The information in
Entry into a Material Definitive Agreement. On January 5, 2024 (the “ Closing Date ”), AtriCure, Inc. (the “ Company ”) and its wholly owned subsidiary, AtriCure, LLC (together with the Company, the “ Borrowers ”), entered into an asset-based credit agreement (the “ Credit Agreement ”) among the Borrowers, JPMorgan Chase Bank, N.A., as administrative agent (in such capacity, the “ Administrative Agent ”), JPMorgan Chase Bank, N.A. (“JPMCB”) and Silicon Valley Bank, a Division of First-Citizen…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
Termination of a Material Definitive Agreement. The information set forth under
Results of Operations and Financial Condition. On January 8, 2024, AtriCure issued a press release announcing its preliminary financial results for the fourth quarter and full year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
Director — Shlomi Nachman: Election of Shlomi Nachman as a director.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.